Literature DB >> 19523751

Basic mechanisms of urgency: preclinical and clinical evidence.

Martin C Michel1, Christopher R Chapple.   

Abstract

CONTEXT: Urgency is the core symptom of the overactive bladder symptom complex, but the underlying mechanisms are not fully understood.
OBJECTIVE: To review clinical and experimental studies related to how bladder filling and urgency are sensed and what causes urgency and to discuss how this process affects potential therapeutic strategies. EVIDENCE ACQUISITION: Review of published reports. EVIDENCE SYNTHESIS: The definition of urgency as a desire implies that it can only be assessed in cognitively intact patients and that animal studies have to rely on surrogate markers thereof, such as detrusor overactivity (DO); however, DO and urgency are not always associated. While the precise mechanisms of how urgency is sensed remain unclear, accumulating evidence suggests that they may differ from the physiologic sensation of bladder filling. Studies on the neurophysiology of urgency sensing are hampered by reliance on the surrogate marker DO. Functional brain imaging may help to understand the central neurophysiology, but, until now, it has not specifically focused on urgency. With regard to causes of urgency, multiple theories have been forwarded. While none of them has been proven, it should be noted that they are not mutually exclusive, and, in specific patients, different causes may be present.
CONCLUSIONS: The development of improved therapeutic strategies against urgency will be helped by a better understanding of how urgency is perceived and the underlying causes. Rigorous use of existing definitions and the search for reliable surrogate markers will aid such attempts.

Entities:  

Mesh:

Year:  2009        PMID: 19523751     DOI: 10.1016/j.eururo.2009.05.028

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  9 in total

Review 1.  β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions?

Authors:  Yasuhiko Igawa; Naoki Aizawa; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-05-03       Impact factor: 8.739

2.  Brain activity underlying impaired continence control in older women with overactive bladder.

Authors:  Stasa D Tadic; Derek Griffiths; Werner Schaefer; Andrew Murrin; Becky Clarkson; Neil M Resnick
Journal:  Neurourol Urodyn       Date:  2012-03-30       Impact factor: 2.696

3.  Pathophysiology of the urothelium and detrusor.

Authors:  Pradeep Tyagi
Journal:  Can Urol Assoc J       Date:  2011-10       Impact factor: 1.862

Review 4.  Overactive bladder in children.

Authors:  Israel Franco
Journal:  Nat Rev Urol       Date:  2016-08-17       Impact factor: 14.432

5.  A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.

Authors:  Ernesto Callegari; Bimal Malhotra; Peter J Bungay; Rob Webster; Katherine S Fenner; Sarah Kempshall; Jennifer L LaPerle; Martin C Michel; Gary G Kay
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

Review 6.  The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Authors:  Karl-Erik Andersson; Nurul Choudhury; Jean-Nicolas Cornu; Moses Huang; Cees Korstanje; Emad Siddiqui; Philip Van Kerrebroeck
Journal:  Ther Adv Urol       Date:  2018-07-06

Review 7.  What are the origins and relevance of spontaneous bladder contractions? ICI-RS 2017.

Authors:  Marcus J Drake; Christopher H Fry; Hikaru Hashitani; Ruth Kirschner-Hermanns; Mohammad S Rahnama'i; John E Speich; Hikaru Tomoe; Anthony J Kanai; Karen D McCloskey
Journal:  Neurourol Urodyn       Date:  2018-01-23       Impact factor: 2.696

8.  Role of KIT-Positive Interstitial Cells of Cajal in the Urinary Bladder and Possible Therapeutic Target for Overactive Bladder.

Authors:  Yasue Kubota; Yoshiyuki Kojima; Yasuhiro Shibata; Makoto Imura; Shoichi Sasaki; Kenjiro Kohri
Journal:  Adv Urol       Date:  2011-07-17

9.  Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

Authors:  V W Nitti; V Khullar; P van Kerrebroeck; S Herschorn; J Cambronero; J C Angulo; M B Blauwet; C Dorrepaal; E Siddiqui; N E Martin
Journal:  Int J Clin Pract       Date:  2013-05-21       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.